News

27 October 2021 – Race Oncology Limited (“Race”) is pleased to announce it has entered into a research collaboration with Dr Dan Dominissini of the Chaim Sheba Medical Center, Israel…

United States Patent No. 11,147,800 entitled COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF 19 October 2021 – Race Oncology (“Race”) is pleased to…

Race Oncology (“Race”) is pleased to announce that it has been issued a new patent (US 11,135,201) from the United States Patent and Trademarks Office (USPTO) for its cancer drug,…

Zantrene at low concentrations kills high FTO producing melanoma cancer cellsSensitivity to Zantrene correlates with FTO levels, where high FTO producing cells show up to 60x greater sensitivity than low…

09 August 2021 – Race Oncology Limited (“Race”) is pleased to announce that the first patient has been dosed in the Phase 1b/2 trial in relapsed/refractory Acute Myeloid Leukaemia (ASX…